stage

AIN
IonescuTx

IonescuTx

location_on West ,  United States

Please note:
Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. This platform is targeted solely at investors who are sufficiently sophisticated to understand these risks and make their own investment decisions. Investors are encouraged to review and evaluate the investments and determine at their own discretion, the appropriateness of making the particular investment. The information on this website is provided for informational purposes only, but we cannot guarantee that the information is accurate or complete. We strongly encourage investors to complete their own due diligence with licensed professionals, prior to making any investment and will not offer any legal or tax advice.

Short Summary

The goal of IonescuTx is to discover disease-modifying small-molecule therapeutics for late-onset Alzheimer's Disease (LOAD). We are focused on correcting ApoE4 function to stop lipid dysregulation in the brain that leads to neurodegeneration.

Highlights

  • ApoE4 is the strongest genetic risk factor for Alzheimer's disease
  • Current approaches focus on plaques and aggregates, which lack efficacy
  • Substantial evidence suggests ApoE4 causes Alzheimer's disease progression
  • Our approach is to correct ApoE4 function to stop Alzheimer's progression
  • We will discover and develop small molecule modulators of ApoE4

Overview

Target $10,000,000
Minimum $10,000
Investment Raised $0
Previous Rounds $0
Stage Pre-Startup/R&D
Investor Role Any

Ask a question
Have a question?

Similar Projects

OKKULO Vision Training

OKKULO Vision Training

location_onUnited Kingdom

OKKULO revolutionises human performance with our prescribe and fix methodology and our cutting-edge light technology, enhancing vision, accelerating brain-muscle connection, and unlocking peak potential - all within a contextual training environment.

  • Multiple International Patents granted
  • Private facility in Arizona for MLB players spring training preparation
  • 1st sale into MLB Franchise

$3,000,000

Total Required

$10,000

Min per Investor
Find out more
The in Between

The in Between

location_onGauteng, South Africa

Serving South Africans unable to afford private services but are able to pay for semi-private alternatives, such as affordable schools. A joint pharmacy venture with the State—providing not free but reliable, accessible, and fairly priced medicines.

  • Quality education for families between public & private options
  • Smaller classes → better student results
  • Affordable, fast access to essential medication

$1,700,000

Total Required

$6,000

Min per Investor
Find out more
Cure For Paralysis

Cure For Paralysis

location_onIsrael

Matricelf develops the first autologous (self) neural implant to repair spinal cord injuries. Backed by strong preclinical data and heading toward First-in-Human trials in early 2026, a key inflection point.

  • The 1st to develop functional neuronal tissue (Micro-Spinal Cord)
  • Autologous (self). Made from the patient own cells. No rejection.
  • 3d structure to accelerate integration.

$3,000,000

Total Required

$25,000

Min per Investor
Find out more
Loading…
Loading the web debug toolbar…
Attempt #